Coagulation and Comorbidity: Determining the Outcomes in Covid Patients (original) (raw)

INTRODUCTION: Hypercoagulability due to severe viral pneumonia is not novel. Patients with COVID-19 pneumonia exhibit coagulation abnormalities, most commonly elevated levels of fibrinogen and D-dimer, often with mild thrombocytopenia. Three stages of COVID-19-associated coagulopathy have been proposed: stage 1 showing elevated D-dimer, stage 2 showing elevated D-dimer together with mildly prolonged PT/INR and aPTT and mild thrombocytopenia, and stage 3 with critical illness and laboratory studies progressing towards classic DIC. METHODOLOGY: The present study is a prospective hospital based cross sectional study Conducted in patients admitted in Intensive care unit at Dr. Shankar Rao Chavan Government Medical College Nanded between April 1st 2021 to April 30th 2021. 312 patients were included in the study. RESULTS: A total of 312 patients were admitted during the study period. The mean age of the patients was 46.43 + 17.13 years, ranging from 19 to 89 years. patients had at least one chronic comorbidity. Hypertension (14.10%), diabetes (10.26%), and both hypertension and diabetes (10.26%). On bivariate analysis the decreased platelet counts and raised APTT and D-Dimer and the presence of co morbidity were statistically significant. Any co morbidity emerged as the independent risk factor for the mortality in multivariate analysis. CONCLUSION: COVID-19 patients with low levels of PLT, high PT and INR that were associated with poor prognosis. The abnormal pattern of coagulation parameters was highly associated with comorbidities and mortality.